Inhibition of ERK signaling in control cancer cells by U0126 treatment (Fig. 8B vs 8A) or a dominant-negative form of MEK-1 (Fig. 8D vs 8C) induced drastic morphological changes similar to those obtained under LRP-1 silencing. Here, MAP2K1 is linked to cancer.